Circio Holding ASA (CRNA) - tidl: Targovax (TRVX) 1

[VBR]

Noen som har fått tildeling av emisjons-aksjer?

[Bompiole]

Fikk 65% av det eg overtegna.Var som sagt stor interesse

[TekBot]

Circio Holding ASA - Preliminary results of the warrant exercise

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN
OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, CANADA,
HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR
…

Vis børsmeldingen

RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY
OF THE SECURITIES DESCRIBED HEREIN.

Oslo, 18 December 2024: Reference is made to the stock exchange announcement
published by Circio Holding ASA (the “Company”) on 4 December 2024, regarding
the first day of the exercise period for the 13,864,852 warrants (the
“Warrants”) issued in connection with the rights issue completed in June and
July 2024 (the “Rights Issue”) and the stock exchange announcement published
earlier today, 18 December 2024 regarding completion of a private placement of
4,903,925 new shares (the “Private Placement”).

The exercise period for the Warrants expired today, 18 December 2024 at 16:30
hours (CET).

The preliminary results indicate that 12,921,088 Warrants were exercised in the
exercise period, resulting in an aggregate allocation of 12,921,088 new shares
in the Company (the “New Shares”) at a subscription price of NOK 0.60 per New
Share to those who exercised Warrants in the exercise period, raising gross
proceeds of approximately NOK 7.7 million.

The final result of allocation of New Shares is expected to be published
tomorrow, on 19 December 2024.

The New Shares will be listed and issued upon registration of the share capital
increase in the Norwegian Register of Business Enterprises as soon as
practically possible, expected end of 2024 or early January 2025. The New Shares
will be listed on the Oslo Stock Exchange under ISIN NO0013033795 and ticker
code “CRNA”.

The New Shares will not be transferred to the holder before they are fully paid
and the share capital increase pertaining to the exercise of the Warrants and
the Private Placement has been registered with the Norwegian Register of
Business Enterprises.

Following the exercise of the Warrants and the Private Placement, the Company’s
share capital will be NOK 42,090,397.20, divided by 70,150,662 shares each with
a nominal value of NOK 0.60.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

Lubor Gaal, CFO
Phone: +34 683343811
Email: lubor.gaal@circio.com

About Circio

Building next generation RNA technology for nucleic acid medicine

Circio Holding ASA is a biotechnology company developing powerful circular RNA
vector expression technology for next generation nucleic acid medicine.

Circio has established a unique circular RNA (circRNA) vector expression
platform for novel DNA, RNA and viral therapeutics. The proprietary circVec
technology is based on a modular genetic cassette design for efficient
biogenesis of multifunctional circRNA inside cells, which can be deployed in
multiple therapeutic settings, including genetic medicine, cell therapy and
chronic disease. The circVec platform has demonstrated up to 15-fold enhanced
and more significantly more durable protein expression vs. classic mRNA vector
systems and has the potential to become a new gold-standard platform technology
for nucleic acid and viral therapeutics in the future. The circRNA R&D
activities are being conducted by the wholly owned subsidiary Circio AB based at
the Karolinska Institute in Stockholm, Sweden.

In addition, Circio is developing a pan-RAS cancer vaccine, TG01, targeting KRAS
driver mutations. TG01 is currently being tested in two clinical trials: RAS
-mutated pancreatic and lung cancer in the USA and multiple myeloma in Norway.
These studies are being run through academic and industry collaborative
networks, supported by prestigious research grants from Innovation Norway and
the Norwegian Research Council, creating read-outs and future optionality for
the program at low cost to Circio.

• IMPORTANT INFORMATION -

This announcement is not and does not constitute an offer of securities for sale
or a solicitation of an offer to purchase securities of the Company in the
United States or any other jurisdiction. Copies of this document may not be sent
to jurisdictions, or distributed in or sent from jurisdictions, in which this is
barred or prohibited by law. The securities of the Company may not be offered or
sold in the United States absent registration or an exemption from registration
under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”).

The securities of the Company have not been, and will not be, registered under
the U.S. Securities Act. Any sale in the United States of the securities
mentioned in this communication will be made solely to “qualified institutional
buyers” as defined in Rule 144A under the U.S. Securities Act. No public
offering of the securities will be made in the United States.

This announcement is an advertisement and is not a prospectus for the purposes
of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14
June 2017 on prospectuses to be published when securities are offered to the
public or admitted to trading on a regulated market, and repealing Directive
2003/71/EC (as amended) as implemented in any EEA Member State (the “Prospectus
Regulation”). Investors should not subscribe for any securities referred to in
this announcement except on the basis of information contained in the
Prospectus. Copies of the Prospectus is made available on the Company’s website.

In any EEA Member State, this communication is only addressed to and is only
directed at qualified investors in that Member State within the meaning of the
Prospectus Regulation, i.e., only to investors who can receive the offer without
an approved prospectus in such EEA Member State.

In the United Kingdom, this communication is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred to
as “Relevant Persons”). These materials are directed only at Relevant Persons
and must not be acted on or relied on by persons who are not Relevant Persons.
Any investment or investment activity to which this announcement relates is
available only to Relevant Persons and will be engaged in only with Relevant
Persons. Persons distributing this communication must satisfy themselves that it
is lawful to do so.

This stock exchange announcement is not for publication or distribution in,
directly or indirectly, Australia, Canada, Japan, the United States or any other
jurisdiction in which such release, publication or distribution would be
unlawful, and it does not constitute an offer or invitation to subscribe for or
purchase any securities in such countries or in any other jurisdiction. In
particular, the stock exchange announcement and the information contained herein
should not be distributed or otherwise transmitted into the United States or to
publications with a general circulation in the United States of America.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as “anticipate”, “believe”,
“continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and similar
expressions. The forward-looking statements in this release are based upon
various assumptions, many of which are based, in turn, upon further assumptions.
Although the Company believes that these assumptions were reasonable when made,
these assumptions are inherently subject to significant known and unknown risks,
uncertainties, contingencies and other important factors which are difficult or
impossible to predict and are beyond its control. Such risks, uncertainties,
contingencies and other important factors could cause actual events to differ
materially from the expectations expressed or implied in this release by such
forward-looking statements. The information, opinions and forward-looking
statements contained in this announcement speak only as at its date and are
subject to change without notice. This announcement is made by and is the
responsibility of the Company.

This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company. No reliance may be
placed for any purpose on the information contained in this announcement or its
accuracy, fairness or completeness.

Kilde

[Chrysler300C]

Egentlig ganske skuffa , jeg ble ringt tidlig av Erik i forrige uke og sa jeg tok 300k av de…

Fikk mail idag og fikk tildelt 125k bare .

Solgte alt på 0,71 og regnet med og få 300k til 0,6 kr

[VBR]

Har nok satt en grense for hva de har inkludert. Tenkte å ta et lite lodd og sa jeg kunne ta 150 000 aksjer. Ikke hørt et kvekk i dag

[TekBot]

Circio raises NOK 10.7 million in upsized offering from new and existing shareholders

· Circio has raised a total of approx. NOK 10.7 million in new capital from the
exercise of warrants and a private placement carried out on 18 December 2024
· Applications for allocation of available warrants were 3 times
…

Vis børsmeldingen

oversubscribed
· The shareholder base has been strengthened by the addition of two new
experienced biotech investors

Oslo, Norway 18 December 2024 - Circio Holding ASA (OSE: CRNA), a biotechnology
company developing powerful circular RNA technology for next generation nucleic
acid medicine, today announces that it has secured approx. NOK 10.7 million in
financing to support the development of its unique and powerful circVec circular
mRNA technology.

Reference is made to two separate announcements made by Circio Holding ASA on 18
December 2024 regarding i) exercise of
warrants (https://www.circio.com/en/circio-holding-asa-preliminary-results-of
-the-warrant-exercise/) and ii) allocation of available warrants and completion
of a private placement (https://www.circio.com/en/circio-holding-asa-allocation
-of-available-warrants-and-private-placement-completed/)

“Following the recently published circVec 3.0 generation data, Circio has
experienced very strong warrant exercise demand, both from existing and new
shareholders. In order to satisfy some of the additional interest and allow
allocation to two new experienced biotech investors, the offering was upsized
with a parallel private placement” said Dr. Erik D Wiklund, CEO at Circio. “The
additional funding will allow Circio to further accelerate the development of
the circVec platform, with the aim of securing our first partnership during
2025. In addition, we now have a strengthened cap-table to support the company
long-term, and a reduced need to draw future tranches from Atlas.”

The major allocations in the financing were to existing shareholders Høse AS and
Bækkelaget Holding AS, and new shareholders Star Kapital AS (v/ Tom A Thorsen)
and an undisclosed Norwegian investor.

The proceeds will be dedicated to accelerating development of Circio’s circVec
circular RNA technology to establish in vivo proof-of-concept for the lead gene
therapy program, and to expand the platform into a novel cell therapy approach.
With the extra funds, Circio expects to defer the need to draw the next Atlas
convertible bond tranche by 2-3 months.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

Lubor Gaal, CFO
Phone: +34 683343811
Email: lubor.gaal@circio.com

About Circio

Building next generation RNA technology for nucleic acid medicine

Circio Holding ASA is a biotechnology company developing powerful circular RNA
vector expression technology for next generation nucleic acid medicine.

Circio has established a unique circular RNA (circRNA) vector expression
platform for novel DNA, RNA and viral therapeutics. The proprietary circVec
technology is based on a modular genetic cassette design for efficient
biogenesis of multifunctional circRNA inside cells, which can be deployed in
multiple therapeutic settings, including genetic medicine, cell therapy and
chronic disease. The circVec platform has demonstrated up to 15-fold enhanced
and more significantly more durable protein expression vs. classic mRNA vector
systems and has the potential to become a new gold-standard platform technology
for nucleic acid and viral therapeutics in the future. The circRNA R&D
activities are being conducted by the wholly owned subsidiary Circio AB based at
the Karolinska Institute in Stockholm, Sweden.

In addition, Circio is developing a pan-RAS cancer vaccine, TG01, targeting KRAS
driver mutations. TG01 is currently being tested in two clinical trials: RAS
-mutated pancreatic and lung cancer in the USA and multiple myeloma in Norway.
These studies are being run through academic and industry collaborative
networks, supported by prestigious research grants from Innovation Norway and
the Norwegian Research Council, creating read-outs and future optionality for
the program at low cost to Circio.

Kilde

[Chrysler300C]

Snart har vel halvparten av pengene gått til børsmeldinger

Får nå håpe det gir resultater utover våren og får vekk Atlas da

[urban66]

Oppsummert dagens meldinge (Claude 3.5):

Positive utviklinger:

1. Finansiering

• Total kapitaltilførsel på 10,7 millioner NOK
• 3 ganger overtegning på tilgjengelige warranter
• Redusert behov for å trekke på Atlas konvertibelt lån (utsatt 2-3 måneder)

2. Nye investorer

• To erfarne biotek-investorer har kommet inn
• Større aksjonærer som deltok:
  • Høse AS (eksisterende)
  • Bækkelaget Holding AS (eksisterende)
  • Star Kapital AS (ny investor)
  • En ikke-navngitt norsk investor (ny)

3. Strategisk bruk av midlene:

• Akselerere utvikling av circVec-teknologien
• Etablere “proof-of-concept” for genterapi-programmet
• Utvide plattformen til ny celleterapi-tilnærming
• Mål om første partnerskap i løpet av 2025

Fremtidsutsikter:

1. Teknologi

• circVec 3.0 har nylig vist lovende data
• 15 ganger bedre proteinproduksjon enn klassiske mRNA-systemer
• Potensiale til å bli ny “gull-standard” for nukleinsyre- og viral-terapi

2. Forretningsutvikling

• Sikter mot første partnerskap i 2025
• Redusert avhengighet av Atlas-finansiering
• Styrket aksjonærbase for langsiktig støtte

For deg som aksjonær betyr dette:

• Selskapet har fått en sterkere finansiell posisjon
• Nye, erfarne biotek-investorer gir økt kredibilitet
• Konkrete mål for 2025 (partnerskap)
• Mindre risiko knyttet til Atlas-finansiering
• Positiv interesse fra markedet (3x overtegning)

Dette fremstår som positive nyheter som styrker selskapets posisjon og gir mer forutsigbarhet for de nærmeste månedene.

[Macken_123]

Var det ikke 75 x proteinproduksjon i følge den siste meldingen…

[strongbuy]

in vivo ja var det 75x increased half-life of crna vs mrna

[Birgitte]

Tror vi ser en gryende interesse for Circio nå blant investorer. Selskapet vil fortsatt være svært lavt priset mcap ca 50 mill etter dagens kurs og de nye aksjer.

[strongbuy]

Får de til det de er på god vei til å gjøre sålangt så venter man vel bare på BP som vil ha dette uansett pris. Da kan det potensielt bli en 100 bagger herfa i årene som kommer.

Juni 2025 går vel avtale ut med Atlas også, circio har vel frem til da 24 mill som kan trekkes og få de ut av verden kanskje før den tid også med partner avtale.

[Birgitte]

Tiden går fort. 19 november meldingen:

• Technical formulation and in vitro analysis of circVec-LNP formulations by Certest have been successful, and the collaboration will now progress to in vivo delivery testing

[TekBot]

Circio Holding ASA - Final results of the warrant exercise

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN
OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, CANADA,
HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR
…

Vis børsmeldingen

RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY
OF THE SECURITIES DESCRIBED HEREIN.

Oslo, 19 December 2024: Reference is made to the stock exchange announcement
published by Circio Holding ASA (the “Company”) on 18 December 2024, regarding
the preliminary results for the exercise period for the 13,864,852 warrants (the
“Warrants”), issued in connection with the rights issue, raising gross proceeds
of approximately NOK 7.7 million, and the stock exchange announcement published
on 18 December 2024 regarding completion of a private placement of 4,903,925 new
shares (the “Private Placement”).

The exercise period for the Warrants expired at 16:30 hours (CET) on 18 December
2024. At the expiry of the exercise period, 12,921,088 Warrants were exercised,
resulting in an aggregate subscription of 12,921,088 new shares in the Company
(“New Shares”) to the subscribers at a subscription price of NOK 0.60 per New
Share, raising gross proceeds of approximately NOK 7.7 million.

The final allocation of the New Shares has now been completed resulting in the
Company allocating a total of 12,921,088 New Shares to investors holding
Warrants.

The New Shares will be listed and issued upon registration of the share capital
increase in the Norwegian Register of Business Enterprises as soon as
practically possible, expected end of 2024 or early January 2025. The New Shares
will be listed on the Oslo Stock Exchange under ISIN NO0013033795 and ticker
code “CRNA”.

The New Shares will not be transferred to the holder before they are fully paid
and the share capital increase pertaining to the exercise of the Warrants and
the Private Placement has been registered with the Norwegian Register of
Business Enterprises.

Following the exercise of the Warrants and the Private Placement, the Company’s
share capital will be NOK 42,090,397.20, divided by 70,150,662 shares each with
a nominal value of NOK 0.60.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

Lubor Gaal, CFO
Phone: +34 683343811
Email: lubor.gaal@circio.com

About Circio

Building next generation RNA technology for nucleic acid medicine

Circio Holding ASA is a biotechnology company developing powerful circular RNA
vector expression technology for next generation nucleic acid medicine.

Circio has established a unique circular RNA (circRNA) vector expression
platform for novel DNA, RNA and viral therapeutics. The proprietary circVec
technology is based on a modular genetic cassette design for efficient
biogenesis of multifunctional circRNA inside cells, which can be deployed in
multiple therapeutic settings, including genetic medicine, cell therapy and
chronic disease. The circVec platform has demonstrated up to 15-fold enhanced
and more significantly more durable protein expression vs. classic mRNA vector
systems and has the potential to become a new gold-standard platform technology
for nucleic acid and viral therapeutics in the future. The circRNA R&D
activities are being conducted by the wholly owned subsidiary Circio AB based at
the Karolinska Institute in Stockholm, Sweden.

In addition, Circio is developing a pan-RAS cancer vaccine, TG01, targeting KRAS
driver mutations. TG01 is currently being tested in two clinical trials: RAS
-mutated pancreatic and lung cancer in the USA and multiple myeloma in Norway.
These studies are being run through academic and industry collaborative
networks, supported by prestigious research grants from Innovation Norway and
the Norwegian Research Council, creating read-outs and future optionality for
the program at low cost to Circio.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 of the Norwegian Securities Trading Act. This stock exchange
announcement was published by Mats Hermansen, VP Finance at Circio Holding ASA,
at the date and time as set out above.

• IMPORTANT INFORMATION -

This announcement is not and does not constitute an offer of securities for sale
or a solicitation of an offer to purchase securities of the Company in the
United States or any other jurisdiction. Copies of this document may not be sent
to jurisdictions, or distributed in or sent from jurisdictions, in which this is
barred or prohibited by law. The securities of the Company may not be offered or
sold in the United States absent registration or an exemption from registration
under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”).

The securities of the Company have not been, and will not be, registered under
the U.S. Securities Act. Any sale in the United States of the securities
mentioned in this communication will be made solely to “qualified institutional
buyers” as defined in Rule 144A under the U.S. Securities Act. No public
offering of the securities will be made in the United States.

This announcement is an advertisement and is not a prospectus for the purposes
of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14
June 2017 on prospectuses to be published when securities are offered to the
public or admitted to trading on a regulated market, and repealing Directive
2003/71/EC (as amended) as implemented in any EEA Member State (the “Prospectus
Regulation”). Investors should not subscribe for any securities referred to in
this announcement except on the basis of information contained in the
Prospectus. Copies of the Prospectus is made available on the Company’s website.

In any EEA Member State, this communication is only addressed to and is only
directed at qualified investors in that Member State within the meaning of the
Prospectus Regulation, i.e., only to investors who can receive the offer without
an approved prospectus in such EEA Member State.

In the United Kingdom, this communication is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred to
as “Relevant Persons”). These materials are directed only at Relevant Persons
and must not be acted on or relied on by persons who are not Relevant Persons.
Any investment or investment activity to which this announcement relates is
available only to Relevant Persons and will be engaged in only with Relevant
Persons. Persons distributing this communication must satisfy themselves that it
is lawful to do so.

This stock exchange announcement is not for publication or distribution in,
directly or indirectly, Australia, Canada, Japan, the United States or any other
jurisdiction in which such release, publication or distribution would be
unlawful, and it does not constitute an offer or invitation to subscribe for or
purchase any securities in such countries or in any other jurisdiction. In
particular, the stock exchange announcement and the information contained herein
should not be distributed or otherwise transmitted into the United States or to
publications with a general circulation in the United States of America.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as “anticipate”, “believe”,
“continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and similar
expressions. The forward-looking statements in this release are based upon
various assumptions, many of which are based, in turn, upon further assumptions.
Although the Company believes that these assumptions were reasonable when made,
these assumptions are inherently subject to significant known and unknown risks,
uncertainties, contingencies and other important factors which are difficult or
impossible to predict and are beyond its control. Such risks, uncertainties,
contingencies and other important factors could cause actual events to differ
materially from the expectations expressed or implied in this release by such
forward-looking statements. The information, opinions and forward-looking
statements contained in this announcement speak only as at its date and are
subject to change without notice. This announcement is made by and is the
responsibility of the Company.

This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company. No reliance may be
placed for any purpose on the information contained in this announcement or its
accuracy, fairness or completeness.

Kilde

[meursault]

Fint for de som kommer inn nå da, for oss som har vært med siden Targovax tiden så holder ikke 100x fra dagens nivå for å hente inn det tapte…

[Frs2904]

Noen som vet når og hvordan de ekstra aksjene skal betales

[Xon]

Betaling bes utført ved første anledning, senest 19/12 klokken 12:00 til:

Kontoeier: Circio Holding ASA
SWIFT: NDEANOKK
Konto nummer.: 6005.06.60667

mats.hermansen@circio.com

E-post mottatt 18.des:

Hei xxxx,

Basert på din søknad om å bli tildelt tilgjengelige warrants og med henvisning til din dagens pressemelding fra selskapet om allokering av slike warrants og gjennomføring av private placement har jeg gleder av å informere om at du har fått følgende tildeling:

0000 aksjer
Beløp som skal betales: NOK 0000

Betaling bes utført ved første anledning, senest 19/12 klokken 12:00 til:

Kontoeier: Circio Holding ASA SWIFT: NDEANOKK Konto nummer.: 6005.06.60667 IBAN#: NO5160050660667
Betalingen merkes med “Navn på person/selskap” som har tegnet seg

De Nye Aksjene vil bli notert og utstedt ved registrering av aksjekapitalforhøyelsen i Foretaksregisteret forventet ved utgangen av 2024 / begynnelsen av januar 2025. Selskapet vil bestrebe seg på å levere de Nye Aksjene så snart som praktisk mulig etter utløpet av tegningsperioden.
Vennligst ta kontakt dersom det skulle være noe spørsmål.

[Moborg]

Hvor har du fått dette? Jeg kan ikke se å ha mottatt noe info om betaling via vps.

[Xon]

E-post fra Mats med info om antall tildelte aksjer ol.

Kort frist … ja.
Kanskje feil også ?

[Multiple]

@Moborg

Jeg kan ikke se å ha mottatt noe info om betaling via vps

Poenget var vel at man IKKE kunne ordne dette via vps.no (euronext.com), og derfor måtte utføre betalingen manuelt til circio?